{"organizations": [], "uuid": "83f8ef0c5ae6029f60871d837b4779f043845a9e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180524.html", "section_title": "Archive News &amp; Video for Thursday, 24 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-recro-pharma-receives-complete-res/brief-recro-pharma-receives-complete-response-letter-from-fda-idUSASC0A3J6", "country": "US", "domain_rank": 408, "title": "BRIEF-Recro Pharma Receives Complete Response Letter From FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.2, "site_type": "news", "published": "2018-05-24T19:23:00.000+03:00", "replies_count": 0, "uuid": "83f8ef0c5ae6029f60871d837b4779f043845a9e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-recro-pharma-receives-complete-res/brief-recro-pharma-receives-complete-response-letter-from-fda-idUSASC0A3J6", "ord_in_thread": 0, "title": "BRIEF-Recro Pharma Receives Complete Response Letter From FDA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "recro pharma inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "brief-recro pharma receives complete response letter from fda", "sentiment": "negative"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "crl", "sentiment": "none"}, {"name": "pharma inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 24 (Reuters) - Recro Pharma Inc:\n* RECRO PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA\n* RECRO PHARMA INC - RECEIVED CRL FROM FDA REGARDING NEW DRUG APPLICATION FOR IV MELOXICAM\n* RECRO PHARMA INC - RECEIVED CRL FROM FDA OFFICE OF DRUG EVALUATION II REGARDING NEW DRUG APPLICATION (NDA) FOR IV MELOXICAM\n* RECRO PHARMA INC - CRL STATES DATA FROM AD HOC ANALYSES & SELECTIVE SECONDARY ENDPOINTS SUGGEST ANALGESIC EFFECT DOES NOT MEET EXPECTATIONS OF FDA\n* RECRO PHARMA INC - CRL RAISED CMC RELATED QUESTIONS ON EXTRACTABLE AND LEACHABLE DATA PROVIDED IN NDA\n* RECRO - CRL STATED ALTHOUGH OUTCOME OF PIVOTAL PHASE III TRIALS WERE STATISTICALLY SIGNIFICANT, FDA UNABLE TO APPROVE APPLICATION IN CURRENT FORM\n* RECRO PHARMA INC - INTEND TO REQUEST A MEETING WITH FDA AS SOON AS POSSIBLE TO DISCUSS POINTS RAISED IN CRL Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-24T19:23:00.000+03:00", "crawled": "2018-05-25T16:32:13.019+03:00", "highlightTitle": ""}